Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) reached a new 52-week low on Monday. The stock traded as low as $27.69 and last traded at $27.65, with a volume of 356,312 shares traded. The stock had previously closed at $28.56.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on COGT. Weiss Ratings reissued a “sell (d-)” rating on shares of Cogent Biosciences in a research note on Friday, October 2nd. Wedbush reaffirmed an “outperform” rating and set a $55.00 price objective on shares of Cogent Biosciences in a research note on Wednesday, September 16th. HC Wainwright upped their price objective on shares of Cogent Biosciences from $55.00 to $56.00 and gave the company a “buy” rating in a research note on Monday, November 9th. Guggenheim increased their price objective on shares of Cogent Biosciences from $45.00 to $52.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, Wall Street Zen cut shares of Cogent Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, September 5th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $53.57.
Read Our Latest Report on COGT
Cogent Biosciences Trading Down 3.4%
The firm has a market capitalization of $4.80 billion, a price-to-earnings ratio of -12.25 and a beta of 0.36. The company has a debt-to-equity ratio of 0.50, a quick ratio of 10.99 and a current ratio of 10.99. The business has a fifty day moving average price of $31.39 and a 200 day moving average price of $35.31.
Cogent Biosciences (NASDAQ:COGT – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The technology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). As a group, equities analysts forecast that Cogent Biosciences, Inc. will post -2.28 earnings per share for the current year.
Hedge Funds Weigh In On Cogent Biosciences
Several hedge funds and other institutional investors have recently modified their holdings of COGT. BlackRock Inc. purchased a new stake in shares of Cogent Biosciences during the 2nd quarter worth about $671,547,000. Wellington Management Group LLP increased its position in Cogent Biosciences by 21.4% during the 2nd quarter. Wellington Management Group LLP now owns 4,343,977 shares of the technology company’s stock worth $168,112,000 after purchasing an additional 765,355 shares in the last quarter. Commodore Capital LP increased its position in Cogent Biosciences by 31.5% during the 1st quarter. Commodore Capital LP now owns 2,888,007 shares of the technology company’s stock worth $111,159,000 after purchasing an additional 691,162 shares in the last quarter. Pictet Asset Management Holding SA raised its holdings in Cogent Biosciences by 18.8% in the third quarter. Pictet Asset Management Holding SA now owns 2,842,776 shares of the technology company’s stock valued at $90,990,000 after buying an additional 449,261 shares during the period. Finally, Siren L.L.C. raised its holdings in Cogent Biosciences by 4.9% in the first quarter. Siren L.L.C. now owns 1,709,279 shares of the technology company’s stock valued at $65,790,000 after buying an additional 80,000 shares during the period.
About Cogent Biosciences
Cogent Biosciences is a clinical-stage biotechnology company developing precision medicines for diseases driven by specific genetic mutations. Its research focuses on targeted therapies intended to address the underlying causes of these conditions. The company’s lead investigational medicine, bezuclastinib, is a selective inhibitor of the KIT protein. Cogent has studied it in clinical programs for systemic mastocytosis and gastrointestinal stromal tumors (GIST), conditions in which abnormal KIT signaling can play a role.
Further Reading
- Five stocks we like better than Cogent Biosciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
